This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas Pharma, Inc.
Drug Names(s): solifenacin succinate, YM905
Description: Vesicare (solifenacin succinate) is an oral selective muscarinic receptor antagonist indicated for the treatment of incontinence, frequency and urgency incontinence for patients with overactive bladder (OAB).
Deal Structure: In August 2003, Yamanouchi and GlaxoSmithKline signed an agreement for the co-promotion of Vesicare in the United States.
In April 2005, Yamanouchi and Fujisawa merged to form Astellas Pharma.
In February 2011, Astellas Pharma announced that its affiliate, Astellas Pharma US, exercised its right under its agreement with co-promotion partner GlaxoSmithKline to assume full commercial responsibility in the US for Vesicare. After a transition period, which is expected to conclude no later than January 2012, GlaxoSmithKline sales representatives will no longer co-promote Vesicare and all such promotional activities will be undertaken by Astellas Pharma US. As consideration for its assumption of full commercial responsibility, Astellas will make certain payments to GlaxoSmithKline until 2015, when the original agreement was set to expire.
Partners: GlaxoSmithKline plc
Additional information available to subscribers only: